€¦ · future science group. Catalogue 2012. future science group. Catalogue 2012. . Contacts ....

future science groupCatalogue 2012

future science group

Catalogue 2012

www.future-science-group.com

Contacts

desi

gned

and

pro

duce

d by

Pur

eprin

t G

roup

018

25 7

6881

1 w

ww

.pur

eprin

t.co

m

UK, USA, Europe, Rest of World

Future Science GroupUnitec House2 Albert PlaceLondon N3 1QB, UK

T: +44 (0)20 8371 6080F: +44 (0)20 8371 6099E: [email protected]

For customers in North America:[email protected]

Far East (excluding Korea, China and Japan)

Roslinda M. RaziMY Mailbox 882251Singapore919191

T: +65 3153 06338E: [email protected]

iGroup Asia PacificUnit 2003A, 20/FCauseway Bay Plaza I489 Hennessy RoadCauseway Bay, Hong Kong

T: +852 2572 7228F: +852 2575 8822E: [email protected]

Republic of Korea

Shinwon Datanet Inc.200-20, Dongkyo-DongMapo-GuSeoul 121-819Korea


China

Charlesworth ChinaFloor 12, Xiandai Baili Dasha(Beijing Modern Palace Building)No.20 Dongsanhuan NanluDaluyuan, Chaoyang DistrictBeijing 100022, China


Japan

Technomics, Inc.Ohku Building Kyobashi1-16-10 KyobashiChuoku, Tokyo 104-0031Japan


India

Informatics (I) Limited194, R V Road, BasvanagudiBangalore - 560 004India

T: +91-80-40387777F: +91-80-40387600E: [email protected]

Middle East

Arabian Advanced SystemsPO Box 20129Riyadh 11455Saudi Arabia


Latin America and the Caribbean

dotLibAv. das Americas3434 - Bloco 2 - Sala 506Rio de JaneiroRJ 22640-102Brazil

T: +55 (21) 3431 3430F: +55 (21) 3431 3480E: [email protected]

Southern Africa

WorldWide Information ServicesPrivate Bag X10072RANDBURG 2125South Africa

T: +27 11 789 9947F: +27 11 789 9967E: [email protected]

1www.future-science-group.com

Dear Colleague

Welcome to Future Science Group’s 2012 Catalogue

New additions for the year ahead…

We are proud to announce the launch of five new journals in 2012 under the Future Medicine and Future Science imprints:

• JournalofComparativeEffectivenessResearch(p. 47)• ColorectalCancer(p. 35)• BreastCancerManagement(p. 32)• LungCancerManagement(p. 48)• PharmaceuticalPatentAnalyst(p. 66)

eBook program launched

The exciting new FSG eBook program is now available, with over 50 titles initially in 2012 and an expanding program throughout the year. Students, researchers and clinicians will be served by a topical collection of fully accessible, illustrated books addressing the most important areas of modern medicine.

All of these new initiatives build on the other recent developments to our established program. Last year saw the launch of five new peer-reviewed journals – DiabetesManagement, PainManagement, ClinicalInvestigation, NeurodegenerativeDiseaseManagement and Neuropsychiatry.

Bioanalysis web resource

In addition, March this year marks the first anniversary of the advent of the Bioanalysis Zone – an innovative web community site providing great content and functionality for the bioanalytical community.

If you would like further information on the eBook program or any of the products and services mentioned then please do not hesitate to contact [email protected] for further details.

Best wishes for 2012,

Future Science Group Team

Unitec House, 2 Albert Place, London, N3 1QB, UKT: +44 (0) 20 8371 6080, F: +44 (0) 20 8371 6089

2

New journals from Future Science Group in 2012

From Future Medicine – tomorrow’s medicine today…

Journal of Comparative Effectiveness Research

The goal of comparative effectiveness research is to assist patients, physicians, purchasers, and policy makers to choose between the available effective treatments in order to improve healthcare delivery at the level of the individual and on a population scale. Through its rigorous evaluation and comprehensive coverage, the Journal ofComparativeEffectivenessResearch provides stakeholders with the key data and opinions to make informed and specific decisions. See p. 47

New titles in oncology

Three new peer-reviewed titles provide concise, readable overviews of current and future options in key areas of cancer diagnosis and management. The journals provide highly accessible information for the busy clinician or healthcare professional. These new titles address

three of the most challenging areas in oncology today – ColorectalCancer (p. 35), Breast Cancer Management (p. 32) and LungCancerManagement(p. 48).

Each journal issue provides:

• High-quality reviews of current and emerging topics

• Cutting-edge editorials discussing contentious issues

• Rapid publication of new original research findings

• Independent drug evaluations assessing individual medicines

• Forward-looking perspectives

• Topical interviews addressing focal issues and controversy

• Disease-specific case studies

From Future Science – revelations in R&D…Pharmaceutical Patent Analyst

PharmaceuticalPatentAnalystprovides a forum in which the most notable recent developments in the pharmaceutical patent literature are expertly unearthed and critically examined within the context of the wider R&D landscape. From small molecules to biologics, top-tier analysis and expert commentary on topical IP issues affecting all stages of the pharmaceutical patent lifecycle provides essential reading both for experienced IP specialists and researchers with IP interests. See p. 66

Future Science Group – Catalogue 2012


Contents1 Welcome

2 New in 2012

5 Expert Reviews8 Expert Review of Anticancer Therapy9 Expert Review of Anti-infective Therapy 10 Expert Review of

Cardiovascular Therapy 11 Expert Review of Clinical Immunology 12 Expert Review of Clinical Pharmacology13 Expert Review of Dermatology 14 Expert Review of Endocrinology

& Metabolism 15 Expert Review of Gastroenterology

& Hepatology 16 Expert Review of Hematology

17 Expert Review of Medical Devices 18 Expert Review of Molecular Diagnostics19 Expert Review of Neurotherapeutics20 Expert Review of Obstetrics

& Gynecology21 Expert Review of Ophthalmology22 Expert Review of Pharmacoeconomics

& Outcomes Research23 Expert Review of Proteomics24 Expert Review of Respiratory Medicine25 Expert Review of Vaccines

27 Future Medicine30 Aging Health31 Biomarkers in Medicine32 Breast Cancer Management33 Clinical Lipidology34 Clinical Practice (formerlyTherapy) 35 Colorectal Cancer36 Diabetes Management 37 Epigenomics38 Future Cardiology 39 Future Microbiology40 Future Neurology 41 Future Oncology42 Future Virology43 Imaging in Medicine44 Immunotherapy

45 International Journal of Clinical Rheumatology

46 Interventional Cardiology 47 Journal of Comparative

Effectiveness Research48 Lung Cancer Management 49 Nanomedicine50 Neurodegenerative Disease

Management51 Neuropsychiatry52 Pain Management53 Personalized Medicine54 Pharmacogenomics55 Regenerative Medicine56 Women’s Health

57 Future Science60 Bioanalysis Zone61 Bioanalysis62 Biofuels63 Carbon Management

64 Clinical Investigation65 Future Medicinal Chemistry66 Pharmaceutical Patent Analyst67 Therapeutic Delivery

68 eBook Collections

70 Information for Authors

71 Information for Librarians

4 Fully indexed and searchable to chapter level

4 Delivered from a single platform, interconnected to other FSG content

4 NO DRM – users can choose how they wish to access content

4 Fully integrated into the library catalogue

4 Free MARC records

4 COUNTER compliant usage statistics

4 OpenURL compliance

ACCESS the mostimportant areas in modern medicine in one collection

www.future-science-group.com/ebooks

5

Critical analysis in modern medicine

The Expert Reviews series of journals delivers systematic, authoritative analysis and insightful commentary from international experts.

4 Fully indexed and searchable to chapter level

4 Delivered from a single platform, interconnected to other FSG content

4 NO DRM – users can choose how they wish to access content

4 Fully integrated into the library catalogue

4 Free MARC records

4 COUNTER compliant usage statistics

4 OpenURL compliance

ACCESS the mostimportant areas in modern medicine in one collection


6

Benefits of the Expert Reviews series• Highly structured format

Each review provides a complete overview of current thinking on a specific topic of research. This is augmented by a specially structured format that maximizes accessibility.

• Timely reviews The Expert Reviews series features timely articles published monthly or bi-monthly by leading experts in the field. This series of journals covers a broad range of scientific fields to ensure that your team is kept up-to-date on the latest advances and techniques in healthcare and clinical practice, whatever your discipline.

• High-quality imagery and tabular data To maximise readability and accessibility, the Expert Reviews journals are produced to the highest production standards featuring our award-winning design, professional layout, high-quality images and graphically enhanced tabular data.

• Acclaimed authors and editorial boards The Expert Reviews series is a leading forum for discussion on clinical medicine – expert advisory panels identify leading authors and hot topics. Through the publication of timely Reviews, News Summaries, Interviews and Special Focus Reports, these journals are the gateway to cutting-edge discussion and debate in the field.

• Rigorous peer-review and a dedicated in-house editorial team A dedicated in-house editorial team ensures that these journals publish the most relevent topics in contemporary clinical medicine all within industry-leading time frames. Each article commissioned is subject to rigorous peer-review by three independent experts, to ensure quality and accuracy of content.

www.expert-reviews.com 7

Contents8 Expert Review of Anticancer Therapy

9 Expert Review of Anti-infective Therapy

10 Expert Review of Cardiovascular Therapy

11 Expert Review of Clinical Immunology

12 Expert Review of Clinical Pharmacology

13 Expert Review of Dermatology

14 Expert Review of Endocrinology & Metabolism

15 Expert Review of Gastroenterology & Hepatology

16 Expert Review of Hematology

17 Expert Review of Medical Devices

18 Expert Review of Molecular Diagnostics

19 Expert Review of Neurotherapeutics

20 Expert Review of Obstetrics & Gynecology

21 Expert Review of Ophthalmology

22 Expert Review of Pharmacoeconomics & Outcomes Research

23 Expert Review of Proteomics

24 Expert Review of Respiratory Medicine

25 Expert Review of Vaccines

Exp

ert

Revi

ews

– Co

nten

ts


Expert Review of Anticancer TherapyISSN: 1473-7140 Volume: Number 12 (2012)Frequency: 12 issues per yearImpact Factor: 2.970

Expert Review of

Anticancer Therapy

Expert Reviews LtdUnitec House2 Albert PlaceLondon, N3 1QB, UKwww.expert-reviews.com

EditorialTel.: +44 (0)20 8371 6090Fax: +44 (0)20 8343 2313

Customer ServicesTel.: +44 (0)20 8371 6080Fax: +44 (0)20 8371 6099Email: [email protected]

Publisher of:Expert Review of Anticancer TherapyExpert Review of Anti-infective TherapyExpert Review of Cardiovascular TherapyExpert Review of Clinical ImmunologyExpert Review of Clinical PharmacologyExpert Review of DermatologyExpert Review of Endocrinology and MetabolismExpert Review of Gastroenterology and HepatologyExpert Review of HematologyExpert Review of Medical DevicesExpert Review of Molecular DiagnosticsExpert Review of NeurotherapeuticsExpert Review of Obstetrics and GynecologyExpert Review of OphthalmologyExpert Review of Pharmacoeconomics and Outcomes ResearchExpert Review of ProteomicsExpert Review of Respiratory MedicineExpert Review of Vaccines

Expert Reviews LtdISSN 1473-7140

June 2010 vol. 10 no. 6

Editorials

Potential of imaging biomarkers for characterization of renal massesCan urinary biomarkers replace cystoscopic examination in bladder cancer surveillance?

drug ProfilE

Trabectedin and liposomal doxorubicin in relapsed ovarian cancer

PErsPEctivEs

Is there a role for presurgical therapy for renal cell carcinoma?Adjuvant vaccination & TKI therapy in patients with surgically resected RCC

rEviEws

First-line sorafenib in selected metastatic renal cell carcinoma patientsRecent advances in prognostic markers for clear-cell renal cell carcinomaUnderstanding the molecular genetics of renal cell neoplasiaThe origins of urothelial carcinomaLatest developments in imaging of bladder cancerCurrent status of radiation therapy for bladder cancerManaging muscle-invasive bladder cancer in the elderlyUnravelling the complexity of cancer–immune system interplayNonhistone protein acetylation as cancer therapy targetsIndividualized therapy of lung cancer with gefitinib: the IPASS trial

Expert R

eview o

f An

ticancer Th

erapy

Expert R

eviews Ltd

Jun

e 2010 vol. 10 n

o. 6

ExpertReviewofAnticancerTherapy provides expert analysis and commentary on the performance of new therapeutic and diagnostic modalities in this new era for oncology.

Coverage includes:• Therapeutic overviews of specific cancers• Performance and benefits of newly approved anticancer agents• New therapeutic indications• Adverse effects – occurrence and reduction• Prospects for medicines in late-stage trials approaching regulatory approval• Combined approaches of chemotherapy and radiotherapy• Epidemiologic studies highlighting prospects for cancer prevention and control• New diagnostic approaches to screening and patient stratification

ExpertReviewofAnticancerTherapy provides a centralized resource of commentary and debate to inform clinical and economic decision-making in healthcare delivery.

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts,Science Citation Index Expanded™ (SciSearch®), Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition®, Index to Scientific Reviews®, Scopus

Exp

ert

Revi

ew o

f Ant

ican

cer

Ther

apy

Expert Review of Anticancer Therapy covers all areas of clinical oncology and is a useful resource for physicians, medical

students, researchers and other healthcare workers in the field of oncology.Simon S Lo, Case Western Reserve University, USA


Expert Review of Anti-infective TherapyISSN: 1478-7210 Volume: Number 10 (2012)Frequency: 12 issues per yearImpact Factor: 3.090

Expert Review of

Anti-infective Therapy






Expert R

eviews Ltd

Expert R

eview o

f An

ti-infective Th

erapy

July 2010 vo

l. 8 no

. 7

ExpertReviewofAnti-infectiveTherapy provides critical analysis and commentary on the latest approaches to the management of bacterial, viral, fungal and parasitic infectious diseases and the development of new anti-infective therapies.

Coverage includes:• Effectiveness and safety of antibiotic agents• Understanding infectious diseases• New and emerging therapeutic approaches• Diagnostic technologies• Antimicrobial resistance• Hospital-borne infections• Increasing prevalence of viral infections• Concerns over the use of infectious agents as weapons of bioterrorism

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts,Science Citation Index Expanded™ (SciSearch®), Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition®, Scopus

Exp

ert

Revi

ew o

f Ant

i-inf

ectiv

e Th

erap

y

The journal publishes state of the art reviews on current issues regarding antimicrobials and antimicrobial therapy….

It is a pleasure to work with the editorial team as they are very professional.George G Zhanel, University of Manitoba Winnipeg, Canada


Expert Review of Cardiovascular TherapyISSN: 1477-9072 Volume: Number 10 (2012)Frequency: 12 issues per year

Expert Review of

Cardiovascular Therapy






Expert R

eviews Ltd

Expert R

eview o

f Card

iovascu

lar Therap

y

July 2010 vol. 8 no. 7

ExpertReviewofCardiovascularTherapy provides expert analysis and commentary, focusing on the clinical performance of new therapeutic and diagnostic modalities in cardiology.

Coverage includes:• Overviews of specific therapeutic areas, highlighting optimal therapy• Performance and benefits of newly approved cardiovascular therapeutic agents• Prospects for new therapies• Psycho–social aspects• Epidemiologic studies and trends• New diagnostic approaches, screening and patient stratification• Pharmacoeconomics and outcomes research

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Emcare, Chemical Abstracts, CINAHL®Plus, Scopus

Exp

ert

Revi

ew o

f Car

dio

vasc

ular

The

rap

y

Expert Review of Cardiovascular Therapy reviews the latest and innovative issues and offers an excellent overview on

new treatment options in cardiovascular medicine. The articles offer a fast and efficient way to keep up to date with the speed of innovations in the field.Thomas Deneke, Academic Heart Center Cologne-Porz, Germany


Expert Review of Clinical ImmunologyISSN: 1744-666X Volume: Number 8 (2012)Frequency: 8 issues per yearImpact Factor: 0.593

Expert Review of

Clinical Immunology





Expert Reviews LtdISSN 1744-666X

Expert R

eviews Ltd

Expert R

eview o

f Clin

ical Imm

un

olo

gy

May 2010 vo

l. 6 no

. 3

May 2010 vol. 6 no. 3

ExpertReviewofClinicalImmunology provides a centralized resource of commentary and debate, helping to inform clinical and economic decision-making in healthcare delivery for immunologic disorders.

Coverage includes:• Therapeutic overviews of specific immunologic disorders• Performance and benefits of newly approved therapeutic agents• New diagnostic approaches• Pharmacoeconomic studies• New therapeutic indications for existing therapies• Adverse effects – occurrence and reduction• Prospects for medicines in late-stage trials approaching regulatory approval• Immunopathophysiology and implications for treatment

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts,Science Citation Index Expanded™ (SciSearch®), Scopus

Exp

ert

Revi

ew o

f Clin

ical

Imm

uno

logy

…the articles in Expert Review of Clinical Immunology represent a paradigm of clear, timely, informative and high-quality reviews

– enabling researchers and clinicians to keep abreast of the ever-changing views and knowledge in this exciting field.Timothy Radstake, University Medical Centre Nijmegen, The Netherlands


Expert Review of Clinical PharmacologyISSN: 1751-2433Volume: Number 5 (2012)Frequency: 6 issues per year

Expert Review of

Clinical Pharmacology






May 2010 vol. 3 no. 3

Expert R

eview o

f Clin

ical Pharm

acolo

gy

Expert R

eviews Ltd

May 2010 vo

l. 3 no

. 3

Special FocuS: ion channelS

Foreword

Welcome to ‘Clinical Pharmacology of Ion Channels’

reviewS

Strategies for the real-time detection of Ca2+ channel events of single cells

Immunopharmacology: utilizing antibodies as ion channel modulators

Pharmacology of ORAI channels as a tool to understand their physiological functions

K+ channels in the heart: new insights and therapeutic implications

hERG and beyond in cardiovascular safety pharmacology

Acid-sensing ion channels: new advances and therapeutic implications

Regulation of cardiovascular TRP channel functions along the NO–cGMP–PKG axis

Regulation of airway mucosal hydration

Na+ channelopathies and epilepsy: recent advances and new perspectives

Therapeutic potential of KCa3.1 blockers: advances and promising trends

Modulation of ion channels in clinical psychopharmacology

ExpertReviewofClinicalPharmacology bridges the gap between the medical profession, clinical research and the pharmaceutical industry, providing researchers, specialists, physicians and other healthcare professionals with the key information they need to facilitate progress in pharmacological therapy.

Coverage includes:• ADME studies and PK/PD modeling• Novel clinical trial design and conduct• Adverse effects/reactions, drug–drug and drug–disease interactions• Toxicology• Pharmacogenetics, genomics and the incorporation of new

biomarkers in drug development and clinical practice• Pharmacoepidemiology, risk management and pharmacovigilance• Regulation of drug development and marketing• Pharmacology in specific patient groups, such as women,

children and the immunocompromised

Citations: EMBASE/Excerpta Medica, Chemical Abstracts, Scopus

Exp

ert

Revi

ew o

f Clin

ical

Pha

rmac

olo

gy

An excellent tool to stay abreast of the current issues in clinical pharmacology for the scientist and clinician.

Arduino Mangoni, University of Aberdeen, UK


Expert Review of DermatologyISSN: 1746-9872 Volume: Number 7 (2012)Frequency: 6 issues per year

Expert Review of

Dermatology






Expert R

eviews Ltd

Expert R

eview o

f Derm

atolo

gy

Jun

e 2010 vol. 5 n

o. 3

ExpertReviewofDermatology provides rapid publication of commentary and analysis on the latest research and clinical advances in all areas of dermatology, highlighting the challenges for the specialty in a new medical era.

Coverage includes:• New understanding of dermatologic disease processes• Diagnostic techniques and preventive strategies• Performance and comparison of existing and novel therapeutic indications• Adverse drug reactions and side-effect profiles• Ethical considerations for clinical and experimental research• Management guidelines and future directions• Screening, patient stratification and epidemiology• Strategic and political issues in dermatology


Exp

ert

Revi

ew o

f Der

mat

olo

gy

Expert Review of Dermatology is a great source of information on important current topics which are relevant to each and

every one of us providing care to skin care patients. The articles are written by experts in dermatology and provide a wonderful resource for all. I encourage reading this Journal from cover to cover.Michael H Gold, Gold Skin Care Center, USA


Expert Review of Endocrinology & MetabolismISSN: 1744-6651Volume: Number 7 (2012)Frequency: 6 issues per year

Expert Review of

Endocrinology & Metabolism






May 2010 vol. 5 no. 3

Expert R

eview o

f End

ocrin

olo

gy &

Metab

olism

Expert R

eviews Ltd

May 2010 vo

l. 5 no

. 3

Editorials

Endocrine treatment of transsexuals

Fat mass and bone development

drug ProfilEs

Repaglinide in combination with metformin for Type 2 diabetes

Conivaptan for the treatment of hyponatremia

KEy PaPEr Evaluation

Brick by brick: metformin for gestational diabetes mellitus?

rEviEws

Subclinical hypothyroidism and subclinical hyperthyroidism

Primary hyperparathyroidism

Primary aldosteronism: an update

Clinical physiology of NAFLD: pathogenesis and treatment

Glucocorticoids, stress and obesity

Prader–Willi syndrome and growth hormone treatment

Issues in the diagnosis and management of adrenocortical carcinomas

ExpertReviewofEndocrinology&Metabolism provides extensive coverage of state-of-the-art research and clinical advancements in the field of endocrine control and metabolism. The journal focuses on screening, prevention, diagnostics, existing and novel therapeutics, as well as related molecular genetics, pathophysiology and epidemiology.

Coverage includes:• Research and clinical advances in a range of endocrine and metabolic diseases• Reviews on topics such as antibody-mediated hyperthyroidism,

male hormonal contraception and bone metabolism• Updates on the impact of clinical and epidemiology studies• Clinical diagnosis and management of a range of endocrine and metabolic diseases• Drug profiles: reviewing reported data on key drugs as they are approved


Exp

ert R

evie

w o

f End

ocr

ino

logy

& M

etab

olis

m

The keyword for Expert Review of Endocrinology & Metabolism is EXPERT! That means that although there are a

plentiful number of journals in the endocrinology field, the papers written for Expert Review of Endocrinology & Metabolism are written by experts.Lev M Berstein, Petrov Research Institute of Oncology, Russia


Expert Review of Gastroenterology & HepatologyISSN: 1747-4124 Volume: Number 6 (2012)Frequency: 6 issues per year






June 2010 vol. 4 no. 3

ExpertReviewofGastroenterology&Hepatology provides systematic, authoritative analysis on the understanding, diagnosis, treatment and prevention of gastrointestinal and liver disease, including interventional and therapeutic advances in cancer, inflammatory diseases, functional gastrointestinal disorders, nutrition, absorption and secretion.

Coverage includes:• Medical, radiological, pathological, biochemical and physiological aspects• Latest advances in our understanding of disease• Advances in diagnostic technologies• Performance and benefits of new and existing drug treatments• Pharmacoeconomics and outcomes research• Perspectives in contentious or emerging areas

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Emcare, Chemical Abstracts, Scopus

Expe

rt Re

view

of G

astro

ente

rolo

gy &

Hep

atol

ogy

Five star reviews – informative, up-to-date and thorough, from key opinion leaders.

Derek Jewell, University of Oxford, UK


Expert Review of HematologyISSN: 1747-4086Volume: Number 5 (2012)Frequency: 6 issues per yearImpact Factor: 0.459

Expert Review of

Hematology






Expert R

eviews Ltd

Expert R

eview o

f Hem

atolo

gy

Editorials

Classification and response criteria in mastocytosis

Risk of childhood leukemia after low-level exposure to ionizing radiation

Hydroxyurea use in sickle cell disease

KEy PaPEr Evaluations

Fermented papaya preparation for b-thalassemia?

Polyphosphates: platelet activation, intrinsic coagulation and inflammation?

rEviEws

Enhancing umbilical cord blood stem cell engraftment in adult patients

Allogeneic hematopoietic cell transplantation: the state of the art

Allogeneic immunotherapy to optimize the graft-versus-tumor effect

CXCL12 and CXCR4 in bone marrow physiology

JAK2 V617F and beyond: aberrant signaling in myeloproliferative neoplasms

Novel treatment regimens for Waldenström’s macroglobulinemia

Novel oral anticoagulants. Part II: direct thrombin inhibitorsJu

ne 2010 vo

l. 3 no

. 3


ExpertReviewofHematology provides commentary and analysis to facilitate best clinical practice in hematology and to translate advances in research – in areas such as immunology, stem cell research, and cell and gene therapy – into the clinical context.

Coverage includes:• Acute and chronic leukemias• Bone marrow and hematopoietic stem cell transplantation• Hodgkin’s disease and Non-Hodgkin’s lymphomas• Immunodeficiency syndromes• Marrow failure syndromes• Multiple myeloma, amyloidosis and myeloproliferative disorders• Hemoglobinopathies• Transfusion medicine

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Scopus

Exp

ert

Revi

ew o

f Hem

ato

logy

Expert Review of Hematology provides an up-to-date, easy to read perspective of the range of fields in hematology by

well-renowned experts. The clinical aspects of each topic are highlighted with a ‘real world’ approach.Giancarlo Castaman, San Bortolo Hospital, Italy


Expert Review of Medical DevicesISSN: 1743-4440 Volume: Number 9 (2012)Frequency: 6 issues per yearImpact Factor: 2.043

Expert Review of

Medical Devices






Expert R

eviews Ltd

Expert R

eview o

f Med

ical Devices

May 2010 vo

l. 7 no

. 3

May 2010 vol. 7 no. 3

Research and development in the medical device arena is multidisciplinary in nature. This, a single review forum – ExpertReviewofMedicalDevices – provides commentary, analysis and debate for all professionals involved in research, development, testing and clinical use of devices.

Coverage includes:• Device performance in a range of clinical settings• Implants and prostheses• Biomedical materials: mechanical, physical, chemical and biological properties• Nanotechnology in device development• Medical imaging and nuclear medicine• Drug delivery devices and device/drug hybrid products

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts,Science Citation Index Expanded™ (SciSearch®), Emcare, Current Contents®/Engineering Computing and Technology, Journal Citation Reports/Science Edition®, Index to Scientific Reviews®, Compendex, Scopus

Exp

ert

Revi

ew o

f Med

ical

Dev

ices

The discussion of leading-edge developments in this field ensures that readers sustain an informed knowledge base to

underpin their own research and development work whether in academia, hospital or industry.Andrew Lloyd, University of Brighton, UK


Expert Review of Molecular DiagnosticsISSN: 1473-7159Volume: Number 12 (2012)Frequency: 8 issues per yearImpact Factor: 4.652

Expert Review of

Molecular Diagnostics






Expert R

eviews Ltd

Expert R

eview o

f Mo

lecular D

iagn

ostics

May 2010 vol. 10 no. 4

May 2010 vo

l. 10 no

. 4

Editorials

Molecular diagnostics and genotyping of MRSA: an update

MSI testing of all colorectal cancers and other LS-related neoplasms

KEy PaPEr Evaluations

Intestinal dysbiosis in IBS: etiological factor or epiphenomenon?

Molecular detection of rhinoviruses

tEchnology rEPort

New technology for rapid molecular diagnosis of bloodstream infections

rEviEws

Imaging and ‘omic’ methods for the molecular diagnosis of cancer

miRNAs as molecular biomarkers of cancer

Down syndrome screening: imagining the screening test of the future

ST2: a novel biomarker for heart failure

Bone marrow microenvironment in myelomagenesis: role in early diagnosis

DNA methylation as a universal biomarker

Clinical diagnostics for homocysteine: a rogue amino acid?

In vitro lung slices: powerful approach for assessment of lung pathophysiology

Obesity, hyperinsulinemia & breast cancer: novel targets & role for metformin

Microfluidic cell arrays in tumor analysis: new prospects for integrated cytomics

ExpertReviewofMolecularDiagnostics publishes leading analysis of the latest advancements in the field of molecular diagnostics including the detection and monitoring of the molecular causes of disease that are being translated into groundbreaking technologies to be used in the clinical diagnostic setting.

Coverage includes:• Application of technological advances in molecular diagnostic medicine• Latest discoveries in oncology diagnostics• Biomarker usage to guide drug development and target

patient groups for personalized medicine• Emerging ‘omic’ diagnostic technologies including: pharmacogenomic,

epigenomic, proteomic and metabolomic technologies• Molecular tools for infectious disease testing• Disease predisposition and inherited genetic disease testing and monitoring• Development and improvement of current molecular diagnostic tests• Tracking of drug–diagnostic co-developments• Regulatory, ethical and payer perspectives in molecular diagnostics

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts,Science Citation Index Expanded™ (Web of Science), Current Contents®/Clinical Medicine, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®

Exp

ert

Revi

ew o

f Mo

lecu

lar

Dia

gno

stic

s

Publishing frontier molecular diagnostics papers in Expert Review of Molecular Diagnostics is always a great

experience and pleasant journey.William Cho, Queen Elizabeth Hospital, Hong Kong


Expert Review of NeurotherapeuticsISSN: 1473-7175Volume: Number 12 (2012)Frequency: 12 issues per year

Expert Review of

Neurotherapeutics






Editorials

Differential diagnosis of depressive illness versus intense normal sadnessProblems diagnosing bipolar disorder in clinical practiceFutility of the autoimmune orthodoxy in multiple sclerosis research

drug ProfilE

Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults

MEEting rEPort

Molecular and cellular mechanisms of neuroprotection and neuroregeneration

rEviEws

Diagnosis and treatment of postpartum bipolar depressionPsychopharmacology of pediatric bipolar disorderCognitive–behavioral therapy for bipolar disorderSleep deprivation in depressionEffectiveness of polyunsaturated fatty acid omega-3 for depression treatment?Neurodegeneration in schizophreniaClinical and psychosocial significance of trauma history in schizophrenia spectrum disordersSuicide in schizophreniaPrevention of schizophreniaManagement of antipsychotic-related weight gainAntioxidant approaches for the treatment for ADAutophagy in AD

Expert R

eview o

f Neu

roth

erapeu

ticsExp

ert Review

s LtdJu

ly 2010 vol. 10 n

o. 7

July 2010 vol. 10 no. 7

ExpertReviewofNeurotherapeutics provides a centralized resource of commentary and debate on emerging opportunities, strategies, and therapeutic and diagnostic modalities to inform decision-making in research, clinical practice and cost-effective neurological care.

Coverage includes:• Therapeutic overviews of specific disease areas, highlighting optimal therapy• Performance and benefits of newly approved neurotherapeutic agents• Emerging strategies and targets• New therapeutic indications• Legal and ethical perspectives• Pharmacoeconomics and outcomes research

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts,Science Citation Index Expanded™ (SciSearch®), Neuroscience Citation Index®,Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition®,Index to Scientific Reviews®, PsycINFO, Scopus

Exp

ert

Revi

ew o

f Neu

roth

erap

eutic

s

Expert Review of Neurotherapeutics provides clinicians with the best guidance and access to expert views on

therapeutic approaches to disorders of the nervous system.Robert M Post, Department of Psychiatry, George Washington University, USA & Bipolar Collaborative Network, USA


Expert Review of Obstetrics & GynecologyISSN: 1747-4108Volume: Number 7 (2012)Frequency: 6 issues per year

Expert Review of

Obstetrics & Gynecology





Expert R

eview o

f Ob

stetrics and

Gyn

ecolo

gy

Expert R

eviews Ltd


May 2010 vol. 5 no. 3

May 2010 vo

l. 5 no

. 3

ExpertReviewofObstetrics&Gynecology provides evaluated, structured commentary from international opinion leaders in this key field of medical endeavor. Reviews are subject to rigorous peer review and produced to industry-leading standards and timelines to ensure a complete solution for professionals working in obstetrics and gynecology.

Coverage includes:• Advances in diagnostic approaches, prenatal diagnosis• Fertility and conception• Contraception: benefits and adverse effects of novel and existing strategies• Maternal–fetal medicine• Reproductive endocrinology and immunology• Performance and benefits of newly approved therapeutic agents• Gynecologic oncology and pathology


Exp

ert

Revi

ew o

f Ob

stet

rics

& G

ynec

olo

gy

Through its comprehensive, up-to-date and balanced commentary, combined with its editorial board of acclaimed

experts, Expert Review of Obstetrics & Gynecology promises to become a leading journal in this important field.Regine L Sitruk-Ware, Rockefeller University, USA


Expert Review of OphthalmologyISSN: 1746-9899Volume: Number 7 (2012)Frequency: 6 issues per year

Expert Review of

Ophthalmology






ExpertReviewofOphthalmology provides an important platform and fresh approach for commentary in this globally significant area, including debate on current and emerging approaches in ocular medicine.

Coverage includes:• Therapeutic approaches in ophthalmic disorders• Visual function and optics• Ocular tumors• Surgical techniques and new instruments• Advanced materials, devices and implantation• Oculoplastics and neuro-ophthalmology• Molecular biology and molecular genetics in ophthalmology• Management of ocular infections and inflammation

This exciting resource provides the ophthalmology community with access to a wealth of high-quality, peer-reviewed information from the leading experts in the field.


Exp

ert

Revi

ew o

f Op

htha

lmo

logy

Expert Review of Ophthalmology provides truly useful and reliable information in a scholarly yet readable format that

permits knowledge transfer with great efficiency. It has become a must-read for the busy clinician.Mark Packer, Oregon Eye Institute, USA


Expert Review of Pharmacoeconomics & Outcomes ResearchISSN: 1473-7167Volume: Number 12 (2012)Frequency: 6 issues per year





Expert R

eviews Ltd

June 2010 vol. 10 no. 3

Jun

e 2010 vol. 10 n

o. 3

Editorials

US healthcare reform: implications for health economics and research

What outcomes should US policy makers compare in CER?

Recent developments in pharmacoeconomic evaluation in Ireland

drug ProfilE

Cost–effectiveness of lenalidomide in multiple myeloma

sPEcial rEPorts

Public drug expenditure in the Republic of Ireland

Side effects of implementing registries and results databases of clinical trials

rEviEws

Interpretation of differential item functioning analyses using external review

Citizen and patient preferences in health: three types of best–worst scaling

Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research

Economics of improved cancer survival rates: better outcomes, higher costs

QALY weights for neurosensory impairments in pediatric economic studies

Pharmacoeconomics of AEDs as adjunctive therapy for refractory epilepsy

Preventing surgical site infections after bariatric surgery

Factors affecting quality of life in epidermolysis bullosa

Society is experiencing major shifts in demographics, technology and economics and these changes are creating dilemmas for a range of stakeholders – including the pharmaceutical industry, healthcare organizations, governments and patients. At the same time, advances in science are resulting in the proliferation of new medicines. Whilst the technological advances are hugely exciting, the reality is that the costs of drug development are spiraling. ExpertReviewofPharmacoeconomics&OutcomesResearch provides commentary and analysis on the relationship between economic factors and clinical prescribing decisions, providing a practical background to informed prescribing decisions and allocation of healthcare resources.

Coverage includes:• Reviews of pharmacoeconomic

and quality-of-life literature• Overviews of outcomes

findings in specific therapeutic areas and disease states

• Decision-making tools• Evidence-based medicine

• Quality-of-life assessment• Trials methodology• Formulary management• Drug utilization review and evaluation• Cost containment strategies• Healthcare policy

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Emcare, CINAHL®Plus, Scopus

Exp

ert

Revi

ew o

f Pha

rmac

oec

ono

mic

s &

Out

com

es R

esea

rch

I have always found Expert Review of Pharmacoeconomics and Outcomes Research very professional in their approach.

Correspondence and feedback to authors is both helpful and rapid and the graphics produced in house are always clear and understandable.Brian Godman, Karolinska Institutet, Sweden


Expert Review of ProteomicsISSN: 1478-9450Volume: Number 9 (2012)Frequency: 6 issues per yearImpact Factor: 4.406

Expert Review of

Proteomics






Expert R

eviews Ltd

Jun

e 2010 vol. 7 n

o. 3

Expert R

eview o

f Proteo

mics

Editorials

Cancer-omics failureSweet receptors mediate the adhesion of the gastric pathogen H. pyloriWhy is it important to analyze the cardiac sarcomere subproteome?

MEEting rEport

Systemizing the structures and structuring the system

KEy papEr Evaluations

Search of influenza A viruses for adaptive mutations to human hostsProteomic profiling of plasma microparticles following deep-vein thrombosis

BooK rEviEw

Neuroproteomics

rEviEws

Mammalian mitochondrial proteomicsProteomic profiling of proteases: tools for granzyme degradomicsDetection and monitoring of asthma and smoking-related lung diseasesHow to unearth your treasure chest via combinatorial peptide ligand librariesMetalloproteomics as an interdisciplinary area involving proteins and metalsProximity ligation assays: a recent addition to the proteomics toolboxIntegrative oncoproteomics strategies for anticancer drug discoveryApplication of 2-DE for studying the variation of blood proteomeStrategies for quantitation of phosphoproteomic data


ExpertReviewofProteomics seeks to collect together technologies, methods and discoveries from the field of proteomics to advance scientific understanding of the many varied roles protein expression plays in human health and disease.

Coverage includes:• Development of protein arrays• Analysis of post-translational modifications• Biological assays• Metabolomics• Protein biomarker discovery• Protein interactions• Protein bioinformatics• Mass spectrometry technology• Applications of proteomics in individualized medicine

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts,Science Citation Index Expanded™ (Web of Science), Biochemistry & Biophysics Citation Index™, Journal Citation Reports/Science Edition®

Exp

ert

Revi

ew o

f Pro

teo

mic

s

Expert Review of Proteomics is one of my key sources for the latest updates on what is novel in the field of proteomics.

I enjoy reading the editorials as they are always insightful and not shy about pointing out what is lacking in proteomics research.Timothy Veenstra, National Cancer Institute, USA


Expert Review of Respiratory MedicineISSN: 1747-6348Volume: Number 6 (2012)Frequency: 6 issues per year






Expert R

eviews Ltd

Expert R

eview o

f Resp

iratory M

edicin

eJu

ne 2010 vo

l. 4 no

. 3

ExpertReviewofRespiratoryMedicine provides evaluated and structured commentary from international leaders in the fields of obstructive, restrictive, vascular and infectious respiratory diseases.

Coverage includes:• Prospects for new and emerging therapeutics• Improved diagnostic methods, including imaging techniques and biomarkers• Advances in the treatment of respiratory infections and drug resistance issues• Disease and treatment issues for defined populations, such as children and the elderly• Respiratory intensive and critical care• Updates on the status and advances of specific disease areas

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Scopus

Exp

ert

Revi

ew o

f Res

pira

tory

Med

icin

e

Expert Review of Respiratory Medicine provides timely reviews of important topics written by leaders in the

respiratory field.Stephen I Rennard, University of Nebraska Medical Center, USA


Expert Review of VaccinesISSN: 1476-0584Volume: Number 11 (2012)Frequency: 12 issues per yearImpact Factor: 4.145

Expert Review of

Vaccines






Expert R

eviews Ltd

Expert R

eview o

f Vaccin

esJu

ne 2010 vo

l. 9 no

. 6

The vaccine field has been transformed by technological advances of the past decade; however, there remain many challenges in the delivery of cost-effective, safe vaccines. ExpertReviewofVaccines provides structured, informed commentary on the development and application of new vaccines and vaccine technologies.

Coverage includes:• Advanced vaccine technologies and delivery systems• Vaccine adjuvants• Prophylactic and therapeutic vaccines• Profiles of vaccine products and their clinical efficacy• Prospects for new vaccine targets and applications• Vaccines in clinical trials

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts,Science Citation Index Expanded™ (SciSearch®), Biobase, Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition®, Index to Scientific Reviews®, Scopus

Exp

ert

Revi

ew o

f Vac

cine

s

Over the past decade Expert Review of Vaccines has established itself as an important journal for researchers and clinicians

looking for timely and relevant articles in the ever-changing vaccine field. The innovative format facilitates readers being able to rapidly focus on the critical messages communicated by authors.Stephen Hoffman, Sanaria Inc., USA

27

Tomorrow’s medicine today

Future Medicine provides cutting-edge coverage of postgenomic medicine. Our publications provide healthcare practitioners and research professionals with a unique source of original research and topical reviews.

28

Benefits of the Future Medicine series• Timely reviews and high-quality original research

This series of journals covers a broad range of scientific fields to ensure that your team is kept up-to-date on the latest advances and techniques in healthcare and clinical practice, whatever your discipline.

• Highly structured format Each article provides a complete overview of current thinking on that topic of research. This is augmented by a specially structured format.

• High-quality imagery and tabular data Produced to the highest production standards and featuring our award-winning design, professional layout, high-quality images and graphically enhanced tabular data.

• Acclaimed authors and editorial boards Future Medicine journals are leading forums for discussion on all aspects of medicine and we work closely with our Senior Editors and expert advisory panels to identify leading authors and hot topics.

• Rigorous peer review and a dedicated in-house editorial team Dedicated in-house editorial team ensures that our journals publish the most relevant topics in contemporary medicine, all within industry-leading time frames. Each article commissioned is subject to rigorous peer review by three independent experts, to ensure quality and accuracy at all times.

• High visibility Our journals are indexed on many of the leading abstracting services including ISI Science Citation Index, MEDLINE, EMBASE and Chemical Abstracts. See individual journals for full details.

• Rapid Publication We offer rapid publication as standard, ensuring the most up-to-date information is processed.

www.futuremedicine.com 29

Contents30 Aging Health

31 Biomarkers in Medicine

32 Breast Cancer Management New in 2012

33 Clinical Lipidology

34 Clinical Practice (formerlyTherapy)

35 Colorectal Cancer New in 2012

36 Diabetes Management

37 Epigenomics

38 Future Cardiology

39 Future Microbiology

40 Future Neurology

41 Future Oncology

42 Future Virology

43 Imaging in Medicine

44 Immunotherapy

45 International Journal of Clinical Rheumatology

46 Interventional Cardiology

47 Journal of Comparative Effectiveness Research New in 2012

48 Lung Cancer Management New in 2012

49 Nanomedicine

50 Neurodegenerative Disease Management

51 Neuropsychiatry

52 Pain Management

53 Personalized Medicine

54 Pharmacogenomics

55 Regenerative Medicine

56 Women’s Health

Futu

re M

edic

ine

– Co

nten

ts

www.futuremedicine.com

30 Future Science Group – Catalogue 2012

Aging HealthISSN: 1745-509X Volume: Number 8 (2012)Frequency: 6 issues per year

Aging Health provides authoritative commentary, assessment and debate on the scientific and clinical issues in healthcare provision for the elderly.

Each issue provides:• Leading Reviews on current and emerging topics relating to the safe and effective

management of therapy in the elderly, all subject to rigorous peer review• Cutting-edge Editorials discussing contentious issues• Drug Evaluations assessing of individual medicines discussing the role of the

therapeutic approach in current treatment practices, written from an independent perspective

• Priority Paper Evaluations reviewing significant, recently published articles carefully selected and assessed by specialists in aging health

• Original Research Articles – highlighting new findings from clinical studies in the elderly

• Forward-looking Perspectives in which authors have the opportunity to present criticisms or address controversy

Citations: EMBASE/Excerpta Medica, Chemical Abstracts, Scopus, Age Info

Agi

ng H

ealth

Aging Health keeps its readers up-to-date with current geriatric practice by highlighting key articles and providing

comprehensive and authoritative reviews on an array of topics relative to the older population.Tzvi Dwolatzky, Ben-Gurion University of the Negev, Israel


Biomarkers in MedicineISSN: 1752-0363 Volume: Number 6 (2012)Frequency: 6 issues per yearImpact Factor: 1.247

Senior Editors:Andre Terzic, Professor of Medicine, Molecular Pharmacology and Experimental Therapeutics, and Medical Genetics, Mayo Clinic College of Medicine, USAScott A Waldman, Samuel M.V. Hamilton Professor and Director, Division of Clinical Pharmacology, Thomas Jefferson University, USA

Biomarkers in Medicine is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers, and their potential and actual applications in medicine. The journal facilitates translation of research knowledge into the clinic to increase the effectiveness of medical practice.

In-depth coverage includes:• Biomarkers in drug discovery and development• Optimum biomarker selection, validation and application• Pharmacokinetic/pharmacodynamic modeling and simulation to improve and refine

drug development• Biomarker application, using pharmacoepidemiology, pharmacogenetics,

pharmacogenomics and functional proteomic techniques• Biomarkers for clinical safety assessment and predicting adverse effects• Bioanalytical method development and validation• Impact of biomarkers on medicine including regulatory and ethical issues

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, EMBiology, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Current Contents®/Clinical Medicine,BIOSIS Previews, BIOSIS Selective Coverage, BIOSIS Reviews Reports and Meetings,Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus

Bio

mar

kers

in M

edic

ine

Biomarkers in Medicine provides context and perspective on the dynamic and rapidly evolving discipline of biomarkers, their

discovery, and their applications in the management of health and disease.Andre Terzic, Mayo Clinic College of Medicine, USAScott A Waldman, Thomas Jefferson University, USA


Breast Cancer ManagementISSN: 1758-1923 Volume: Number 1 (2012)Frequency: 4 issues in 2012, increasing to 6 per year

part of

Breast Cancer Management

January 2012 Vol. 1 Issue 1

EDITORS | Martin Grabois & Andrew SC Rice

Highlights in this issueEditorial | M BondPain and its management in developing countries

Interview | BJ SesslePain management challenges: research, access, costs, education and public awareness

Case Series | TT Reid, RA Demme & TE QuillWhen there are no good choices: illuminating the borderland between proportionate palliative sedation and palliative sedation to unconsciousness

Review | CL von Baeyer et al.Pain charts (body maps or manikins) in assessment of the location of pediatric pain

BreastCancerManagement addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy.

BreastCancerManagement provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances in clinical practice in the field are reported and analyzed by international experts. The journal presents this information in using clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts.

Coverage includes:• Diagnosis and imaging• Surgical approaches• Radiotherapy• Systemic therapies• Cancer clinical trials• Genetic aspects of disease• Personalized medicine• Translational research and biomarker studies• Management of psychological distress• Epidemiological studies• Pharmacoeconomics• Evidence-based treatment guidelines

Brea

st C

ance

r M

anag

emen

t

New in2012


Clinical LipidologyISSN: 1758-4299 Volume: Number 7 (2012)Frequency: 6 issues per yearImpact Factor: 0.556

Lipid-related illnesses are set to impose a huge burden on healthcare in the coming years, with lipids playing an important role in many areas of research. ClinicalLipidology reports on the major advances in lipidology research and assists the health community in meeting these challenges.

Coverage includes:• The genetics and molecular biology of lipid disorders and metabolism• Related cardiovascular diseases, such as atherosclerosis• Obesity and the metabolic syndrome• Therapeutic overviews of optimal treatment strategies and future trends• Results of recent clinical trials relevant to the field of lipidology• Treatment of lipid-related disorders and side effects of lipid-lowering medication• Lipids in health and disease

ClinicalLipidology provides accessible and definitive analysis across all aspects of lipids in health and disease.

Citations: EMBASE/Excerpta Medica, Chemical Abstracts, EMBiology, Science Citation Index Expanded™ (SciSearch®), Journal Citation Reports/Science Edition®, Scopus

Clin

ical

Lip

ido

logy

Clinicians need a concise, up-to-date resource to guide them in decision making. Clinical Lipidology brings vital information to

practitioners in a concise, comprehensive way.Karol Watson, David Geffen School of Medicine, USA


Clinical Practice (formerly Therapy)ISSN: 2044-9038 Volume: Number 9 (2012)Frequency: 6 issues per year

Senior Editors: Gregory Lip, Professor of Cardiovascular Medicine, Director of the Hameostasis, Thrombosis and Vascular Biology Unit, Birmingham University, UKJames Larkin, Consultant Medical Oncologist at The Royal Marsden Hopsital, Renal Cancer Unit, Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, UKSammy I McFarlane, Associate Professor of Medicine, Division of Endocrinology, SUNY Downstate and Kings County Hospital, USA

ClinicalPractice provides a forum to address key issues across medical practice by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in day-to-day situations. The journal addresses all aspects facing clinical practitioners today, from exploring unmet therapeutic needs to analyzing the implications of real-world evidence, applications of clinical guidelines and multidisciplinary approaches to care.

Coverage includes:• Application of Phase III clinical trial results in clinical practice• Findings from Phase IV/postmarketing studies• Understanding of unmet clinical needs and therapeutic burden• Practical approaches to disease management• Evidence-based treatment guidelines• Multidisciplinary team approaches to care

The journal plays a key role in highlighting practice-changing findings and exploring the implications for contemporary medicine.


Clin

ical

Pra

ctic

e

Offers true opportunities for high-quality research as well as high-value commentaries, reviews and other special

articles written by renowned experts in their fields.Samy I McFarlane, SUNY Downstate and Kings County Hospital, USA


Colorectal CancerISSN: 1758-194X Volume: Number 1 (2012)Frequency: 6 issues per year

Senior Editor: Heinz-Josef Lenz, Scientific Director, USC/Norris Cancer Genetics Unit, Associate Director, USC/Norris Gastrointestinal Oncology Program, Associate Professor of Medicine, Keck School of Medicine, University of Southern California, USA

Colorectal cancer is a major cause of morbidity and mortality, particularly in the developed world. Risk factors for colorectal cancer are on the rise in many countries; populations are aging, and obesity and diabetes are increasing. National screening programs are helping to detect cancer while it is still curable; however, colorectal cancer remains the third leading cause of cancer deaths in the USA and options are still limited for those with more advanced disease.

Research into diagnosis and optimum treatment of the disease is progressing rapidly, with new advances reported every day. ColorectalCancer presents reviews, analysis and commentary on all aspects of colorectal cancer.

ColorectalCancer provides a concise, readable overview of current and future management options in a fast-moving field, ideal for the busy clinician or healthcare professional.

Coverage includes:• Risk factors and prevention• Hereditary nonpolyposis colorectal cancer and other hereditary conditions• Biomarkers for screening• Colonoscopy and sigmoidoscopy for screening and diagnosis• Surgery & radiation therapy• Optimum chemotherapy regimes to maximize efficacy and minimize side effects• Monoclonal antibodies• Multimodality treatment• Prospects for new treatments, such as vaccines• Treatment of metastases• Follow-up care for colorectal cancer survivors

Colo

rect

al C

ance

r

New in 2012


Diabetes ManagementISSN: 1758-1907Volume: Number 2 (2012)Frequency: 6 issues per year

Associate Editors:Philippe Froguel, Chair in Genomic Medicine, Division of Medicine, Imperial College London, London, UKCamillo Ricordi, Scientific Director and Chief Academic Officer of the University of Miami Diabetes Research Institute, University of Miami, USAJaako Tuomilehto, Professor of Public Health, University of Helsinki, Finland

DiabetesManagement offers systematic coverage of the very latest advances in the treatment and prevention of diabetes mellitus, including molecular, genetic and physiological aspects. Through a unique mixture of reviews, perspectives and original research, DiabetesManagement provides cutting-edge perspectives on Type 1 and Type 2 diabetes.

Coverage includes:• Latest advances in the understanding of the disease• Prospects for new therapeutic approaches• Pathogenesis of diabetes and its complications• Pharmacological mechanisms of drug and hormone action• Diabetes as a risk factor, and complications of disease• Pharmacoeconomic issues and outcomes studies

Dia

bet

es M

anag

emen

t

Citations: Chemical Abstracts

Diabetes Management is a much welcomed addition to the multi-disciplined diabetes practitioners worldwide. With its

focused articles and brief summaries, it allows a wide variety of time-constrained diabetes professionals to keep abreast of the latest science and technology in this field.Itamar Raz, Hadassah Hospital, Israel


EpigenomicsISSN: 1750-1911 Volume: Number 4 (2012)Frequency: 6 issues per yearImpact Factor: 3.429

Senior Editors:Jörg Tost, Centre National de Génotypage, FranceJames G Herman, Associate Professor of Oncology, John Hopkins Oncology Center, USA

As we continue to shed light on the inner workings of the genome, Epigenomics offers a critical overview of the latest and most significant advances in this emerging field as they unfold and explores their potential application in the clinical setting. Through a balanced mix of original research and reviews it provides a unique forum for addressing the significant progress in this rapidly expanding research field.

Coverage includes:• DNA methylation profiling and array technologies in epigenomics• Involvement of epigenomics in the diagnosis and prognosis in human disease• Epigenomics in oncology• Cutting-edge epigenomic techniques and tools• Epigenetic mechanisms and effects• Therapeutic implications of the epigenome

Citations: EMBASE/Excerpta Medica, Chemical Abstracts, BIOSIS Previews,BIOSIS Reviews Reports and Meetings, Science Citation Index Expanded™ (SciSearch®), Journal Citation Reports/Science Edition®, Scopus

Epig

eno

mic

sEpigenomics is unique in its field with a balanced mixture of up-to-date research articles, comprehensive review articles

written by key players in their field of research and institutional and personal profiles giving a face to epigenetic research.Jörg Tost, Centre National de Génotypage, France


Future CardiologyISSN: 1479-6678Volume: Number 8 (2012)Frequency: 6 issues per year

Research advances have contributed to improved outcomes across all medical specialties but the rate of advancement in cardiology has been exceptional. Exciting developments in electrical and mechanical devices, cell therapy and xenotransplantation coupled with a growing understanding of cardiac function and disease are already delivering real benefits. FutureCardiology publishes reviews, perspectives and clinical research findings.

Coverage includes:• Molecular basis of cardiovascular disease• Therapeutic overviews highlighting optimal therapies and future options• Interventional, surgical and psychosocial aspects of cardiovascular disease• Novel therapeutics and combination medicines• Advances in diagnostics• Epidemiology• Pharmacoeconomic and outcomes issues in cardiology

Futu

re C

ard

iolo

gy

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Scopus

Future Cardiology brings high-quality peer reviewed and clinically relevant contemporaneous developments in

cardiovascular disease to the readership in a timely manner.Farack Mookadam, Mayo Clinic, USA


Future MicrobiologyISSN: 1746-0913 Volume: Number 7 (2012)Frequency: 12 issues per yearImpact Factor: 2.755

FutureMicrobiology provides an interdisciplinary forum to debate findings and opinions for all scientists working in the field today, bringing together the diverse subject areas of bacteriology, mycology, parasitology and virology.

Coverage includes:• The molecular basis of microbial diseases and microbe–host interactions• Overviews highlighting optimal therapeutic and diagnostic approaches• The use of microbes in the treatment of disease and genetic engineering• Summaries evaluating newly approved antimicrobial agents• New and re-emerging microbes impacting human health• Microbial genome research and the implications for higher organisms

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, CAPCAS, EMBiology, Biobase, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Science Citation Index Expanded™ (SciSearch®), Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus

Futu

re M

icro

bio

logy

Since its launch in 2006, Future Microbiology has become a respected and comprehensive journal with timely articles and

reviews covering the major areas of microbiology (viruses, bacteria, fungi and parasites), with an emphasis on their biomedical and clinical relevance.Jörg Tost, Centre National de Génotypage, France


Future NeurologyISSN: 1479-6708Volume: Number 7 (2012)Frequency: 6 issues per year

FutureNeurology publishes original research together with authoritative commentary and analysis to address the important challenges and advances arising in the translation of laboratory advances into the clinic in neurology.

Coverage includes:• Pathophysiological mechanisms involved in neurological dysfunction• Novel targets for disease therapy• Clinical implications and applications for biomarkers of disease• Genetic contributions to neurological disorders• Impact of molecular genetics on prevention, screening, diagnosis and treatment• Modeling disease and directing therapy• Selective and ‘personalized’ approaches

Futu

re N

euro

logy


Future Neurology brings essential information in a highly authoritative compact format, anticipating and fulfilling

the needs of neurologists.George Perry, The University of Texas at San Antonio, USA


Future OncologyISSN: 1479-6694 Volume: Number 8 (2012)Frequency: 12 issues per yearImpact Factor: 2.455

FutureOncology provides an important forum for the oncology community as we enter a new era of cancer care. The journal focuses on the most important advances and explores their relevance in the clinical setting. The journal publishes reviews, perspectives, original research studies and more.

Coverage includes:• Changing patterns of disease and new findings in cancer etiology• Impact of molecular genetics on prevention, screening, diagnosis and treatment• Integration of diagnostic and therapeutic approaches• Pharmacoeconomics and cost–benefit issues in cancer• Adverse events and drug safety• Profiles of new anticancer agents• Selective and ‘personalized’ approaches

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Current Contents®/Clinical Medicine, Scopus

Futu

re O

nco

logy

Future Oncology excels in providing the clinical and scientific community with information that is not only

authoritative, but cutting edge and relevant.Philip Arlen, National Cancer Institute, USA


Future VirologyISSN: 1746-0794Volume: Number 7 (2012)Frequency: 12 issues per yearImpact Factor: 1.2

Advances in genomics are revealing a host of new insights into viral biology: from phylogenetics and epidemiology, to the molecular basis of disease; antiviral development to novel diagnostics. FutureVirology uses clear and concise article formats to provide a forum for international experts to present their findings and to discuss and evaluate all aspects of virology.

Coverage includes:• Molecular basis of viral disease • Virus–host interactions • Overviews highlighting optimal therapeutic and diagnostic approaches• Summaries evaluating newly approved antiviral agents • Viral drug resistance• Vaccine development and the prevention of viral disease• The use of viral vectors in gene therapy and functional genomics

Futu

re V

irolo

gy

Citations: EMBASE/Excerpta Medica, Chemical Abstracts, CAPCAS, EMBiology, Biobase, Science Citation Index Expanded™ (SciSearch®), Journal Citations Report/Science Edition®, Scopus

Future Virology is a solid resource for information on emerging viruses, drug resistance, virus–host interactions,

therapeutics and vaccine development efforts.Steve Polyak, University of Washington, USA


Imaging in MedicineISSN: 1755-5191 Volume: Number 4 (2012)Frequency: 6 issues per year

Senior Editor:Elliot K Fishman, Professor of Radiology and Oncology, Director, Diagnostic Imaging and Body CT, Johns Hopkins Hospital, USA

ImaginginMedicine provides highly structured commentary and analysis regarding advanced imaging technologies and applications. It presents original research findings, publishes comprehensive profiles of imaging techniques, technologies and the materials used in the clinical and drug research settings, and explores risk issues and societal issues.

Coverage includes:• Clinical applications of imaging technologies – guidelines, experience and best

practice• Computed tomography, MRI, PET and sonography• Translation of technological advance into clinical practice• Transition from structural to functional imagery• Imaging applications in drug discovery, diagnostics and personalized medicine• Imaging biomarkers


Imag

ing

in M

edic

ine

Imaging in Medicine presents cutting-edge articles by leading researchers from around the world in a timely, user-friendly

format. Image quality and presentation are state of the art.Elliot K Fishman, John Hopkins School of Medicine, USA


ImmunotherapyISSN: 1750-743XVolume: Number 4 (2012)Frequency: 12 issues per yearImpact Factor: 0.542

Senior Editors:Yutaka Kawakami, Keio University School of Medicine, JapanFrancesco M Marincola, National Cancer Institute, USADavid C Wraith, University of Bristol, UK

Immunotherapy offers the scientific community an interdisciplinary forum, providing them a platform for the presentation of new findings together with interpretation of the most recent advances of various aspects of immunotherapeutics to aid navigation of this complex field.

Coverage includes:• Cancer immunotherapy, including cancer vaccines and passive immunotherapeutic

approaches• Restorative immunotherapy for AIDS and other immunocompromised patients• Suppressive immunotherapy for autoimmune diseases and transplantation• Drug delivery systems, drug combinations and drug–drug interactions• Summaries evaluating newly approved immunotherapeutic agents• Newly identified immune targets of drugs

Imm

uno

ther

apy

Citations: MEDLINE, Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Biological Abstracts, BIOSIS Previews, Science Citation Index Expanded™ (SciSearch®), Journal Citation Reports/Science Edition®, Scopus

Immunotherapy provides a timely discussion of current topics related to the understanding of human immune biology and

the resulting applications for the treatment of immune pathologies. A highly recommended read for healthcare professionals in the immunotherapy field.Francesco M Marincola, National Institutes of Health, USA


International Journal of Clinical RheumatologyISSN: 1758-4272 Volume: Number 7 (2012)Frequency: 6 issues per year

InternationalJournalofClinicalRheumatology publishes new clinical findings and expert opinion on key advances in the field, providing an authoritative but accessible forum for this expanding area of research.

Coverage includes:• Therapeutic overviews of optimal treatment strategies and future trends• Original research reports of new clinical findings• Emerging treatment options, such as gene and stem cell therapy• Summaries of newly approved therapeutic agents• Biologic processes involved in rheumatic conditions• Personalized medicine in rheumatology


Inte

rnat

iona

l Jou

rnal

of C

linic

al R

heum

atol

ogy

Provides an excellent opportunity for well-respected leaders in the field to present new hypotheses, updates and critical

analyses of current problems facing rheumatologists today.Paul P Tak, Academic Medical Center/University of Amsterdam, The Netherlands


Interventional CardiologyISSN: 1755-5302Volume: Number 4 (2012)Frequency: 6 issues per year

Senior Editors:Eberhard Grube, Chief Division of Structural Heart Disease, International Heart Centre Rhein-Ruhr, GermanyRon Waksman, Associate Director, Division of Cardiology, and Director of Experimental Angioplasty & Emerging Technologies for the Cardiovascular Research Institute (CRI), Washington Hospital Center, USA

InterventionalCardiology charts the advances of this vibrant and dynamic subspecialty and provides a unique resource for interventionalists seeking to keep pace with the unfolding technologies. InterventionalCardiology provides a forum for commentary, debate and new findings as the scope for the potential application of these technologies becomes increasingly complex.

Coverage includes:• Diagnostics• Imaging technologies• Angioplasty and stenting• Drug-eluting stents• Catheterization techniques• Atherectomy• Embolic protection• Peripheral arterial disease• Percutaneous mitral valve replacement and repair• Endovascular repair• Treatment of arrhythmias, including cardiac resynchronization and pacing devices• Cell therapy

Inte

rven

tiona

l Car

dio

logy

Citations: EMBASE/Excerpta Medica, Scopus

In a clear and concise manner Interventional Cardiology effectively and cohesively delivers a diverse spectrum of

current informative material to a global audience.Ron Waksman, Washington Hospital Center, USA


Journal of Comparative Effectiveness ResearchISSN: 2042-6305 Volume: Number 1 (2012)Frequency: 6 issues per year

Senior Editors:Sheldon Greenfield, Donald Bren Professor of Medicine, Executive Director, Health Policy Research Institute, University of California, USAEugene Rich, Senior Fellow and Director, Center on Health Care Effectiveness, Mathematica Policy Research, USA

Through rigorous evaluation and comprehensive coverage, JournalofComparativeEffectivenessResearch provides stakeholders (including patients, clinicians, healthcare purchasers and health policy makers) with the key data and opinions to make informed and specific decisions on clinical practice.

Coverage includes: • Studies of effectiveness or comparative effectiveness yielding new findings

relating to diagnostics, therapeutics, surgical procedures, or other healthcare services or options

• Studies of the comparative safety of different treatment options• Systematic reviews of available evidence relating to the pros and cons of healthcare

options for specific patient groups• Perspectives and debate relating to the performance of comparative effectiveness

studies and best practice issues• Commentary on both patient-relevant outcomes and economic implications• Direct ‘head-to-head’ comparisons of available diagnostic and therapeutic options

– evaluating clinical alternatives with current standard of care• Clinical trial commentaries – evaluating and interpreting the findings of recently

completed CER trials as well as presenting the design and rationale of newly commenced studies

• Pharmacoeconomic studies, health economics and outcomes research

Jour

nal o

f Com

para

tive

Effe

ctiv

enes

s Re

sear

ch

New in 2012

With an accelerating comparative effectiveness research agenda, there will be a growing need for peer-reviewed

publication of this research. The new Journal of Comparative Effectiveness Research will be uniquely positioned and is very timely.Robert Dubois, National Pharmaceutical Council, USA


Lung Cancer ManagementISSN: 1758-1966Volume: Vol 1 (2012)Frequency: 6 issues per year

The strong link between smoking rates and lung cancer incidence has resulted in varying rates of disease within different populations whether on a geographic, socioeconomic or gender basis. What is clear is that, in spite of declining disease rates among some groups in certain developed countries, the disease remains a highly significant global burden. For example, the US National Cancer Institute has estimated the national cost of lung cancer treatment exceeds $10 million.

LungCancerManagement provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts, and the importance of most recent advances in the molecular biology are explained.

The journal presents this information in using clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP2

Coverage includes:• Biological therapies• Biomarkers• Clinical trials• Comparative effectiveness• Diagnosis & imaging• Molecular biology of disease• Molecular diagnostics• Pharmacoeconomics• Radiotherapy• Risk and prevention• Surgical approaches• Systemic therapies

Lung

Can

cer

Man

agem

ent

New in 2012


NanomedicineISSN: 1743-5889 Volume: Number 7 (2012)Frequency: 12 issues per yearImpact Factor: 6.202

Senior Editors:Kostas Kostarelos, Senior Lecturer and Deputy Head, Centre for Drug Delivery Research,The School of Pharmacy, University of London, UKCharles R Martin, Director, Center for Research at the Bio/Nano Interface, University of Florida, USA

As our knowledge of the human body continues to advance, nanotechnology will be developed to monitor, repair and control human biological systems at the molecular level. This will offer unique opportunities for developing new therapeutic strategies to diagnose, prevent, treat and eradicate life-threatening diseases and conditions, as well as resolving pain and improving medical techniques, through various novel nanotechnological approaches. Nanomedicine is a uniquely medicine-focused journal, addressing the important challenges and advances in medical nanoscale-structured material and devices, biotechnology devices and molecular machine systems and nanorobotics, delivering this essential information in concise, clear and attractive article formats.

Coverage includes:• Principles of nanomedicine, including basic research and theoretical applications• Nanotechnological advances and their potential medical applications• Benefits of nanomedical tools versus traditional techniques• Therapeutic applications of nanotechnology• Drug delivery using nanoparticles• Commercialization, funding and economics of nanomedical technology

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Biotechnology Citation Index®, Current Contents®/Life Sciences, Journal Citation Reports/Science Edition®, Inspec®, Scopus

Nan

om

edic

ine

In 2012, there is only one journal at the top of nanomedical research and development – the standard bearer –

Nanomedicine.Chuck Martin, University of Florida, USA


Neurodegenerative Disease ManagementISSN: 1758-2024Volume: Number 2 (2012)Frequency: 6 issues per year

Associate Editors:Anthony H Schapira, Head of the Department of Clinical Neuroscience at the UCL Institute of Neurology and Chairman of Clinical Neurosciences Specialties, University College London, UKBruno Dubois, Director of the Cognitive Neurology Department and the Alzheimer’s Center, Hospital La Salpêtrière, France

The prevention and treatment of neurodegenerative disorders represents a critical goal for current medical research teams. Bringing together the latest commentary and analysis from across a broad spectrum of practice and research, NeurodegenerativeDiseaseManagement promotes a truly multidisciplinary approach to developing new treatments for neurodegenerative diseases.

Coverage includes:• Advances in the treatment of all neurodegenerative diseases, including Alzheimer’s

and Parkinson’s disease, multiple sclerosis and Huntington’s disease• Discoveries in etiology, neurobiology, diagnosis, imaging, treatment and therapy• Diagnosis and predictive medicine• Stem cell technology and emerging treatments• New molecular mechanisms in neurodegeneration• Biomarker development and application

Neu

rod

egen

erat

ive

Dis

ease

Man

agem

ent

The format of the new journal is innovative, and promises to respond to the needs of both clinicians and researchers

working in this broad field.Alessandro Di Rocco, New York University School of Medicine, USA


NeuropsychiatryISSN: 1758-2008 Volume: Number 2 (2012)Frequency: 6 issues per year

Senior Editors:Wayne Goodman, Mount Sinai School of Medicine, USAF Markus Leweke, Central Institute for Mental Health, Germany

This new international, peer-reviewed journal focuses on the study of mental disorders and interventions to target problems in behavior, emotion and cognition. Through a mixture of original research, news, reviews and comment. Neuropsychiatry addresses all the latest trends in the field, from R&D through to clinical application and management.

Coverage includes:• Therapeutic overviews of optimal treatments strategies and future trends• Advances in the treatment of all neuropsychiatric diseases, including schizophrenia

and bipolar disorders, epilepsy and other seizure disorders, obsessive-compulsive and eating disorders

• Cognitive neuropsychiatry• Diagnosis and management• Therapeutic drug monitoring• Adverse effects of drugs in neuropsychiatry

Neu

rop

sych

iatr

yNeuropsychiatry’s scope is to deliver highly relevant and timely papers for both clinicians and basic researchers in the field.

F Markus Leweke, Central Institut of Mental Health, Germany


Pain ManagementISSN: 1758-1869Volume: Number 2 (2012)Frequency: 6 issues per year

Senior Editors:Martin Grabois, Professor and Chairman, Baylor College of Medicine, USAAndrew SC Rice, Professor of Pain Research, Imperial College London, UK

This peer-reviewed, multi-disciplinary journal provides a forum for commentary and debate for a growing community of pain specialists. Bringing together the latest research findings and reviews in pain medicine and pain management, this journal is a vital addition to the literature. The audience includes anesthesiologists, neurologists, physiatrists, psychiatrists, personnel working within pain clinics and other specialists with an interest in the development and application of approaches to pain management.

Coverage includes:• Treatments and techniques in interventional pain management and pain medicine• Advances and breakthroughs in the treatment of chronic and acute pain• Cancer, neuropathy and referred pain• Novel methods in drug application for pain management• Future role of personalized medicine in the development of therapeutics for pain• Palliative care and quality of life

Pain

Man

agem

ent

Pain Management was launched in 2011 with a goal of providing updated information in a scientific format for pain

clinicians, educators and researchers. To date, we are on our way to meeting our goal.Martin Grabois, Baylor College of Medicine, USA


Personalized MedicineISSN: 1741-0541 Volume: Number 9 (2012)Frequency: 8 issues per yearImpact Factor: 0.783Published in partnership with the Personalized Medicine Coalition

Senior Editor:Edward Abrahams, Executive Director, Personalized Medicine Coalition, USA

PersonalizedMedicine translates recent genomic and proteomic advances into the clinical context, and addresses the impact of pharmacogenomics in modern medicine, providing an integrated forum for all players involved in the healthcare value chain.

Coverage includes:• News and opinion from the Personalized Medicine Coalition• Advances in molecular diagnostics with respect to individualizing medicine• Cost–benefit issues for personalized medicine• Impact of personalized medicine on healthcare and the pharmaceutical industry• Impact of the latest concepts in the development of personalized medicine based

on pharmacogenomics, pharmacogenetics and pharmacoproteomics

The journal addresses scientific, commercial and policy issues in personalized medicine and includes news and views, concise commentary and analysis, reports from the conference circuit and full review articles. Articles submitted to PersonalizedMedicine are subject to rigorous peer review.

Citations: EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition®, Scopus

Pers

ona

lized

Med

icin

ePersonalized Medicine covers not only the science, but also the business and policy considerations that underline the

emergence of this new paradigm in health care. It is essential reading for anyone interested in the subject. The Personalized Medicine Coalition is proud and please to support the journal.Edward Abrahams, Personalized Medicine Coalition, USA


PharmacogenomicsISSN: 1462-2416Volume: Number 13 (2012)Frequency: 16 issues per yearImpact Factor: 3.876

Senior Editors:Howard L McLeod, Director, UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, USAMunir Pirmohamed, NHS Chair of Pharmacogenetics, MRC Centre for Drug Safety Sciences, The University of Liverpool, UKDavid Gurwitz, Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Israel

Advances in pharmacogenomics are facilitating the development of therapeutics that are tailored toward specific diseases in specific individuals. As a consequence, physicians will be able to administer the best available drug therapy on the basis of an individual patient’s genotype. Pharmacogenomics focuses on those aspects of this rapidly expanding field that are of the most direct relevance to industrial and academic R&D scientists and to the wider clinical community.

Coverage includes:• Advances in the identification and characterization of genetic polymorphisms

associated with drug responses, drug metabolism and adverse drug reactions to individualize treatment

• Up-to-date reviews on the clinical application of genomic information to pharmacology• Emerging and existing technologies for accessing and exploiting genomic

information implicated in drug development• Ethical and policy issues in pharmacogenomics

Phar

mac

oge

nom

ics

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index®, Science Citation Index Expanded™ (SciSearch®), Biotechnology Citation Index™, Journal Citation Reports/Science Edition®, Index to Scientific Reviews®, Scopus

Pharmacogenomics has become a leading journal in the field because of its rapid publication of cutting edge science

and timely reviews.Howard L McLeaod, UNC Institute for Pharmacogenomics and Individualized Therapy, USA


Regenerative MedicineISSN: 1746-0751 Volume: Number 7 (2012)Frequency: 6 issues per yearImpact Factor: 3.358

Senior Editor:Chris Mason, Professor of Regenerative Medicine Bioprocessing, University College London, UK

Apart from answering some of the most fundamental questions of biology and stem cell research, regenerative medicine offers unprecedented opportunities for developing new medical therapies for debilitating and life-threatening diseases.RegenerativeMedicine is the award winning forum for a fast-growing community of specialists to address the important challenges and advances that are now occurring in stem cell research and regenerative medicine. It delivers this essential information in concise, clear and attractive article formats.

Coverage includes:• Bench-to-bedside translation and scale-up of stem cell and regenerative

medicine therapies• Potential application for stem cell-based strategies in pathological conditions• Stem cell pluriopotency and emerging technologies• Tissue engineering and characterization of engineered tissues• Medical devices and artificial organ development• Regulatory and reimbursement issues• Ethical and legal perspectives

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Emcare, Biological Abstracts, BIOSIS Previews, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus

Rege

nera

tive

Med

icin

eRegenerative Medicine is the leading international publication exclusively committed to the advancement of cell and tissue-

engineered therapies. Contained within its pages is the very latest on the science, clinical translation and the regen industry, a one-stop shop for regenerative medicine information.Chris Mason, University College London, UK


Women’s HealthISSN: 1745-5057Volume: Number 8 (2012)Frequency: 6 issues per year

Women’s physiology and hormonal changes across the life cycle demand important consideration when determining healthcare management options in certain diseases. Age- and gender-related factors can directly affect treatment outcomes. There are also certain conditions that are far more prevalent in women than men and these may require special attention. Women’sHealth provides the forum for commentary and analysis of those diseases and conditions that are of critical importance to women for an audience of clinicians, research scientists, decision-makers and a range of professionals in the healthcare community.

Coverage includes:• Leading Reviews on current and emerging topics relating to the safe and effective

management of therapy in women• Original Research Articles presenting the latest clinical findings• Editorials, Drug Evaluations, Perspectives and Priority Paper Evaluations, all written,

selected and assessed by specialists in women’s health• Coverage expanding beyond women-specific conditions, such as reproductive

health and breast/ovarian cancer, to embrace the unique pathophysiology of disease in women and the corresponding effect on treatment

Wo

men

’s H

ealth

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Emcare, Chemical Abstracts, Scopus

Women’s Health provides vital information on topical and important issues in women’s health across the lifespan.

JoAnn E Manson, Harvard Medical School, USA

57

Revelations in R&D

Future Science specializes in the publication of new findings and high-quality commentary and analysis in today’s key areas of research endeavor. Coverage reflects those areas that most impact our daily lives, our infrastructure for sustainable development and the associated technologies that will allow society to co-exist in harmony with the environment.

58

Benefits of the Future Science series• Timely reviews and high-quality original research

This series of journals cover a broad range of scientific fields to ensure that your team is kept up-to-date on the latest advances and techniques.

• Highly structured format Each article provides a complete overview of current thinking on that topic of research, structured for accessibility.

• High-quality imagery and tabular data Produced to the highest production standards featuring our award-winning design, professional layout, high-quality images and graphically enhanced tabular data.

• Acclaimed authors and editorial boards Future Science journals are leading forums for debate in R&D and we work closely with our Senior Editors and expert advisory panels to identify leading authors and hot topics.

• Rigorous peer-review and a dedicated in-house editorial team Our dedicated in-house editorial team ensures that we publish the most relevant topics all within industry-leading time frames. Each article commissioned is subject to rigorous peer review by three independent experts, to ensure quality and accuracy at all times.

• High visibility Our journals are indexed on many of the leading abstracting services including ISI Science Citation Index, MEDLINE, EMBASE and Chemical Abstracts. See individual journals for full details.

• Rapid Publication We offer rapid publication as standard ensuring the most up-to-date information is processed.

www.future-science.com 59

Contents60 Bioanalysis Zone

61 Bioanalysis

62 Biofuels

63 Carbon Management

64 Clinical Investigation

65 Future Medical Chemistry

66 Pharmaceutical Patent Analyst New in 2012

67 Therapeutic Delivery

Futu

re S

cien

ce –

Co

nten

ts

www.future-science.com


BioanalysisISSN: 1757-6180Volume: Number 4 (2012)Frequency: 24 issues per yearImpact Factor: 1.337

Senior Editors:Brian Booth, Deputy Director, US FDA, Division of Clinical Pharmacology 5, USAHoward Hill, Group Director Pharmaceutical Development, Huntingdon Life Sciences, UK

Bioanalysis is a fortnightly publication focusing on the development, implementation and performance of analytical technologies that enable scientists to obtain specific, selective, sensitive and reproducible data regarding a drug and its metabolites in biological samples.

Coverage includes:• Analyte extraction and

sample preparation• Biomarker assays• Chromatography and

separation sciences• Data processing and statistics• Diagnostic assays and test kits• Drug and metabolite assays• Innovative bioanalytical methods

• Laboratory automation and efficiency• Ligand–binding assays• Mass spectrometry and other

key detection methods• Method development and

validation reports• New instrumentation and equipment• Pharmacogenomics assays• Regulatory and compliance issues

Bioanalysis delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative and accessible forum for the modern bioanalyst.

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Science Citation Index Expanded™ (SciSearch®), Scopus

Bio

anal

ysis

Bioanalysis is a one-stop shop for all those scientists and professionals working in the field of bioanalysis; a single

journal where you can find all articles you need to keep you up-to-date!Fabio Garofolo, Algorithme Pharma Inc., Canada


Senior Editors:Yusuf Chisti, Professor of Biochemical Engineering, Massey University, New ZealandTimothy Donohue, Professor of Bacteriology, University of Wisconsin-Madison, USA

Biofuel research is occurring at an unprecedented rate, with the development of new feedstocks and improvements in production processes providing the key to the transformation of biomass into a global energy resource.

Biofuels provides a forum for all stakeholders in the bioenergy sector, featuring review articles, policy updates, original research articles, commentaries, news and interviews with key opinion leaders, and much more.

Coverage includes:• Sustainable production of annual, perennial and wood feedstocks from agriculture• Creation of new biomass feedstocks in laboratories• Biochemical conversion techniques• Fermentation, anaerobic digestion and enzyme development• Bioenergy systems and plant engineering• Implementation, improved efficiency and reduced environmental impact

of first generation biofuels, including ethanol and biodiesel• New bioenergy sources: algae, genetically engineered fuels

and biochemical carbon dioxide conversion• Coverage of policy and management issues for the

establishment of a global bioenergy market

Citations: CAB Abstracts, Compendex, El Encompass, Scopus

BiofuelsISSN: 1759-7269 Volume: Number 3 (2012)Frequency: 6 issues per year

Bio

fuel

s

Many types of oils and hydrocarbons are being considered as potential biofuels. Biofuels provides a place to find the latest

breakthroughs in the process and control of their synthesis.Timothy Donohue, University of Wisconsin-Madison, USA


Carbon ManagementISSN: 1758-3004Volume: Number 3 (2012)Frequency: 6 issues per year

Senior Editors:Shobhakar Dhakal, National Institute for Environmental Studies, JapanRichard A Houghton, Deputy Director, Woods Hole Research Center, USA

CarbonManagement captures the range of expertise and innovative enquiry represented by the diverse disciplines contributing to enhancing our comprehension of carbon interactions – from meteorology, hydrology, geology and botany to economics, land management, architecture and engineering – and disseminates their collective findings.

Coverage includes:• Natural cycles, sinks and sources of carbon and other greenhouse gases in

relation to terrestrial, aquatic, marine and atmospheric environments• Impacts of anthropogenic activities, such as transport, energy, the

built environment and food, on greenhouse gas emissions• Management processes to measure, assess and mitigate associated carbon emissions

at all scales, from country level through to industry, business and the individual• Policy initiatives to regulate, finance, incentivize and

account for reductions in carbon emissions• Adaptation measures to address the impacts of climate change

Citations: CAB Abstracts, Compendex, El Encompass, Scopus

Carb

on

Man

agem

ent

Carbon Management has captured the attention of scientists and policy makers alike, representing the range of disciplines

that investigate the carbon cycle and inform its management.Richard A Houghton, Woods Hole Research Center, USA


Senior Editor:E. Michael Lewiecki, Clinical Assistant Professor of Medicine, New Mexico Clinical Research & Osteoporosis Center, USA

ClinicalInvestigation is dedicated to systematic coverage of the design, methodology, progress and outcomes of clinical trials. As a peer-reviewed, monthly publication ClinicalInvestigation provides a forum for the rapid publication of original research and critical reviews examining the latest developments in medical research, from Phase I trials through to postmarketing studies and pharmacoeconomic research.

Coverage includes:• Clinical study design and methodology• Overviews of the clinical progress

of new drugs or drug classes• Clinical progress for specific

diseases or therapeutic areas• Findings in Phase I to IV clinical studies• Comparative effectiveness research• Healthcare outcomes and

pharmacoeconomics

• Patient stratification and individualized therapies

• Commentary on trials in progress• Drug safety issues and

adverse event monitoring• Biomarkers in clinical trials• Regulatory issues• Clinical trial data management

and statistics

ClinicalInvestigation provides a systematic program of peer-reviewed coverage relating to the clinical evaluation of new and established therapies. The audience for ClinicalInvestigation includes clinical investigators, healthcare decision makers, formulary managers, clinicians, regulatory personnel and medical affairs professionals.

Citations: Chemical Abstracts

Clinical InvestigationISSN: 2041-6792 Volume: Number 2 (2012)Frequency: 12 issues per year

Clin

ical

Inve

stig

atio

n Clinical Investigation is an international forum for communicating and evaluating the vast amount of information

associated with the clinical development of new therapeutic agents.E Michael Lewiecki, New Mexico Clinical Research & Osteoporosis Center, USA


Future Medicinal ChemistryISSN: 1756-8919Volume: Number 4 (2012)Frequency: 18 issues per yearImpact Factor: 1.424

Senior Editors:Iwao Ojima, Director of Institute of Chemical Biology and Drug Discovery, Stony Brook University, USA David Thurston, Head of the Department of Pharmaceutical and Biological Chemistry, University of London, UK

FutureMedicinalChemistry offers a forum for the rapid publication of original research and critical reviews covering the latest milestones in the field – from the identification of targets, through to the discovery, design, synthesis and evaluation of bioactive agents. Strong emphasis is placed on ensuring that the journal stimulates awareness of issues that are anticipated to play an increasingly central role in influencing the future direction of pharmaceutical chemistry.

Coverage includes:• Drug discovery technologies• Design and synthesis of

novel lead compounds• Computational approaches to

synthesis and modeling• Biophysical techniques for

structural characterization

• Overviews of novel therapeutic strategies and emerging targets

• Drug targeting and delivery• ADME/Tox investigations• Commentary on science policy,

economic, regulatory and IP issues

The journal is a valuable reference, not only for medicinal chemists, but for all those interested in the advancement of pharmaceutical science.

Citations: MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Science Citation Index Expanded™ (SciSearch®), Chemistry Citation Index®, Journal Citation Reports/Science Edition®, Scopus

Futu

re M

edic

inal

Che

mis

try

Future Medicinal Chemistry provides a fresh, much-needed platform for the dissemination of succinct reviews and original

research in medicinal chemistry.Brian SJ Blagg, The University of Kansas, USA


Pharmaceutical Patent AnalystISSN: 2046-8954Volume: Number 1 (2012)Frequency: 5 issues in 2012

Senior Editors:Lyn Jones, Pfizer, USADavid Rotella, Montclair State University, USA

PharmaceuticalPatentAnalyst provides a forum in which the most notable recent developments in the pharmaceutical patent literature are expertly unearthed ad critically examined within the context of the relevant wider R&D landscape. Each issue will address topical IP issues affecting all stages of the pharmaceutical patent lifestyle

The journal publishes articles that highlight the most important, promising and recent patents of relevance to pharmaceutical science across all therapeutic areas, from small molecules to biologics. The journal also features articles exploring IP issues affecting all stages of the pharmaceutical patent lifecycle.

Coverage includes:• Trends and developments in the patent literature• Compounds and agents of therapeutic potential from small molecules to biologics• Developments with potential applications across all therapeutic areas• Inventions in other relevant areas, including biomedical materials,

biotechnology, drug delivery and medical devices• Commentary, opinion and analysis of wider IP issues

of significance to pharmaceutical R&D

The journal provides a key resource for research managers, decisions-makers and IP specialists engaged in pharmaceutical R&D who need to remain abreast of developments in the patent literature while also enhancing their understanding of associated IP issues.

Phar

mac

eutic

al P

aten

t A

naly

st

New in 2012


Therapeutic DeliveryISSN: 2041-5990Volume: Number 3 (2012)Frequency: 12 issues per year

In a highly competitive industry, TherapeuticDelivery provides the busy researcher with a forum for the rapid publication of original research and critical reviews of all the latest relevant and significant developments, and focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients.

Coverage includes:• Delivery of small molecule drugs,

vaccines, radionuclides, proteins, peptides, genes, siRNA, nucleotides, stem cells and diagnostic probes

• Targeting at the molecular, cellular organ and systematic levels

• Techniques for crossing biological barriers

• Methods for enhancement of pharmacokinetic profiles

• Biodynamic and bioresponsive delivery

• Stimuli triggered delivery• Parenteral delivery• Nanotechnology• Personalized therapeutic delivery• Combination products

and delivery devices• Invitro, invivo and insilico

delivery studies• Emerging technologies• Intellectual property, competitor

intelligence and partnering news• Cost–benefit analyses

The delivery community draws together disciplines such as biology, chemistry, pharmacology and pharmaceutics, nanotechnology, physiology, materials science and engineering. TherapeuticDelivery serves this community with highly informed and structured coverage, including reviews, original research, perspectives, commentary and news features.

Citations: EMBASE/Excerpta Medica, Chemical Abstracts, Scopus Th

erap

eutic

Del

iver

y

Therapeutic Delivery provides a comprehensive update across diverse disciplines that enables scientists to identify and apply

in research and development the optimal delivery vehicle for a drug molecule, while maintaining the simplicity of use for the patients.Steven Dinh, Noven Pharmaceuticals, Inc., USA

68

The Future Science Group eBook collection

50 brand new titles in 2012!

Instant access to a new collection at the cutting edge of post-genomic medicine...

Find the latest hot topics covered fully in key areas including:

• Cardiology• Dermatology• Hematology• Immunology• Infectious Diseases• Neurology• Oncology• Respiratory Medicine• Vaccines

Great authors and rapid publication times mean that we can deliver the very latest information, illustrated and presented to the highest standards.

The Collection is available on one existing, tried-and-tested platform, fully integrated and searchable with the Future Medicine journal list content

Flexible collection and license options

Future Science Group eBooks are offered for one-off purchase as an annual package, or via a subscription model. The full Collection and subsets are available through flexible access models to suit your institution’s specific needs. Contact us to find out more about our pricing and license options at [email protected]

Future Science Group eBooks – meeting the needs of the librarian…

• Perpetual access and ownership• NO DRM – users can choose how to access content• Fully integrated into the library Catalogue• Free MARC records• COUNTER compliant usage statistics• OpenURL compliance

To obtain a full bibliographic listing, and access information please contact us directly at [email protected] or call us on +44 (0)20 8371 6080.



eBook title list

Series eISSN 2047-332X

Key new titles include:

• Addressing Unmet Medical Needs in COPD Management• Advances in Acute Coronary Syndrome Management• Advances in Alzheimer’s Disease Management• Advances in Asthma Management• Advances in Bone Metastasis Management• Advances in Ovarian Cancer Management• Advances in Pancreatic Cancer Treatment• Advances in Parkinson’s Disease Management• Advances in Personalized Therapy for Lung Cancer• Advances in the Management of Triple-Negative Breast

Cancer• Analgesics for Cancer Pain• Antidepressants & Major Depressive Disorder• Clinical Applications of Renin–Angiotensin System

Inhibitors• Current & Emerging Pharmaceutical Treatments for Cystic

Fibrosis• Diagnostics, Therapeutics & Vaccines for Tuberculosis• Drug-Eluting Stents• Emerging Oral Medications for Multiple Sclerosis• Emulsion-based Vaccine Adjuvants• Human Papillomavirus Vaccines• Management of Advanced Gastric Cancer• Management of Hypertension in Diabetes• mTOR Inhibitors in Cancer Treatment• Novel Immunologic Adjuvants• Pharmacological Treatments in Schizophrenia• Plant-derived Vaccines: Technologies & Applications• Pneumococcal Conjugate Vaccines• Stroke Prevention in Atrial Fibrillation• Targeted Therapies for Non-Small-Cell Lung Cancer• Targeted Therapies for Renal Cell Carcinoma• Triptans for Migraine

For a full list of all our eBook titles including ISBNs and pricing information please visit


70

Information for AuthorsUnsolicited contributions to Future Science Group journals are actively encouraged. A full explanation if our editorial policies and author opinions is available at the website for each of the Future Science Group imprints. Please see www.expert-reviews.com, www.futuremedicine.com or www.future-science.com for full details.

If you have any queries about submitting a manuscript to any FSG title or participating in our book program, please contact Laura Dormer (Senior Editor) at [email protected]

Future Science Group titles endorse the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, issued by the International Committee for medical Journal Editors, and Code of Conduct for Editors of Biomedical Journals, produced by the Committee on Publication Ethics. Our full Editorial Policy can be found in the Author Guidelines. All journals operate a full author disclosure & conflict of interest policy.

Why publish with the Future Science Group?

• Fast-track publication as standard – all articles are published online within 12 weeks of first draft submission. Accelerated publication options are also available, with a submission to online publication timeline of within 6 weeks pending successful peer review.

• No page charges• Indexing in major databases• Award-winning standards of journal presentation• High-quality platform of both clinical research data and reviews

Future Science Group titles publish a range of article types, including solicited and unsolicited reviews, perspectives and original research articles. Receipt of all manuscripts will be acknowledged within 1 week and authors will be notified as to whether the article is to progress to eternal review.

If you are interested in submitting an article, or have any queries regarding article submission, please contact Laura Dormer (Senior Editor) at [email protected]. For new article proposals, please provide a very brief article outline and working title in the first instance.


71

Information for LibrariansUnique coverage from bench to bedside of the latest developments in healthcare and biomedical research.

Access to electronic content is via:www.expert-reviews.comwww.futuremedicine.comwww.future-science.com

Electronic licenses and collectionsFuture Science Group electronic licenses include a selection of journals or entire collections – providing the user with perpetual coverage of the latest developments in healthcare and biomedical research. Our ‘selected’ collections, grouped by field, are available at special discounted prices for institutions, libraries and consortia.

Library Administration Area – benefit from your own specifically enhanced access interface. Benefitsinclude:• Desktop access 24/7• Rapid Publication• Special Focus Issues• Web feeds (RSS)• Table of Content e-alerts• Searchable online archives• Reference linking within and beyond

Future Science Group• Content listed on CrossRef Search

Services for site license customers• Flexible purchasing• Accessible for all institution types• COUNTER compliant usage reports• ATHENS & Shiboleth authentication

compliance• Reliable publishing platform• Dynamic customer services• Promotion tools upon request

How site license pricing is calculatedPricing is calculated using: Institution type• Academic/Hospitals – prices are

independent of institutional size

• Corporate, Government – bands based on Research and Development staff figure and no. of research sites

• Consortia, multi-site and global organizations – please contact your local sales representative

Free trials – institutions can trial site license access to any publication to evaluate content and online functionality. Free trials provide online access via IP authentication and usage statistics will be provided. To request a free trial, please contact: [email protected]

eTOC RSS Feeds – receive news of the latest research straight to your desktop with our FREE electronic table of contents alerts (eTOC) and RSS feeds.

Consortia – Future Science Group works with consortia of various types and sizes and welcomes discussion with all consortium managers. COUNTER-compliant usage statistics are provided for each institution. The benefits for the consortium include discounts on list price. Members have the flexibility to select the publications they want to include, or Future Science Group will work with the consortium to create customized packages.

Indexing – all Future Science Group titles are abstracted and indexed in all the main databases including MEDLINE/Index Medicus, EMBASE/Excerpta Medica.

Ordering Information – contact:[email protected] for further information.

Institutional subscriptions – Future Science Group operates a pricing model in which the type and size of the subscribing institution determines the subscription rate.

Personal subscriptions – are available to all other titles.


FSG image collection

FSG bespoke

We have an extensive catalogue of medical and scientific images available for purchase

• We create high-quality bespoke scientific and medical illustrations based on your initial concept

• Each team member is a trained illustrator and graduate life scientist who will ensure: – eye-catching artwork – scientific accuracy – accessibility of information for the viewer

For further information regarding our graphics services please contact: Karen Rowland, Head of Graphics and Design, [email protected]

future science groupCatalogue 2012

future science group

Catalogue 2012


Contacts

desi

gned

and

pro

duce

d by

Pur

eprin

t G

roup

018

25 7

6881

1 w

ww

.pur

eprin

t.co

m

UK, USA, Europe, Rest of World

Future Science GroupUnitec House2 Albert PlaceLondon N3 1QB, UK


For customers in North America:[email protected]

Far East (excluding Korea, China and Japan)

Roslinda M. RaziMY Mailbox 882251Singapore919191

T: +65 3153 06338E: [email protected]

iGroup Asia PacificUnit 2003A, 20/FCauseway Bay Plaza I489 Hennessy RoadCauseway Bay, Hong Kong


Republic of Korea

Shinwon Datanet Inc.200-20, Dongkyo-DongMapo-GuSeoul 121-819Korea


China

Charlesworth ChinaFloor 12, Xiandai Baili Dasha(Beijing Modern Palace Building)No.20 Dongsanhuan NanluDaluyuan, Chaoyang DistrictBeijing 100022, China


Japan

Technomics, Inc.Ohku Building Kyobashi1-16-10 KyobashiChuoku, Tokyo 104-0031Japan


India

Informatics (I) Limited194, R V Road, BasvanagudiBangalore - 560 004India

T: +91-80-40387777F: +91-80-40387600E: [email protected]

Middle East

Arabian Advanced SystemsPO Box 20129Riyadh 11455Saudi Arabia


Latin America and the Caribbean

dotLibAv. das Americas3434 - Bloco 2 - Sala 506Rio de JaneiroRJ 22640-102Brazil

T: +55 (21) 3431 3430F: +55 (21) 3431 3480E: [email protected]

Southern Africa

WorldWide Information ServicesPrivate Bag X10072RANDBURG 2125South Africa

T: +27 11 789 9947F: +27 11 789 9967E: [email protected]

€¦ · future science group. Catalogue 2012. future science group. Catalogue 2012. . Contacts ....

Documents

Transcript of €¦ · future science group. Catalogue 2012. future science group. Catalogue 2012. . Contacts ....